Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Sees Drop in Q4 Earnings and R&D Spending, Net Losses Widen

NEW YORK, March 4 - Genome Therapeutics reported today a fall-off in revenues for the fourth quarter ended December 31, 2002, along with lower R&D spending and a slightly increased net loss.


The company posted revenues of $5.8 million for the quarter, down from $8.9 million in the fourth quarter of 2001.


Research and development expenses for the quarter fell to $7.1 million, compared to $10.5 million in the same period of 2001. For the year, the company's R&D spending increased to $32 million from $24 million in the prior year. Genome Therapeutics attributed this increase to clinical development of its Phase III anti-infective candidate, Ramoplanin, as well as increased investment in internal research programs in anti-infectives and chronic human diseases. Total expenses for the quarter were down, at $14.5 million compared to $17.3 million for the fourth quarter of 2001.


The company's net loss widened to $8.8 million for the quarter, or $0.38 per basic and diluted share, compared to a net loss of $7.9 million, or $0.35 per basic and diluted share for the same period of 2001.


Genome Therapeutics had $51 million in cash, cash equivalents, restricted cash, and marketable securities at the end of 2002, compared to $67 million at the end of 2001. The company's current cash holdings include $15 million raised through a convertible financing last year. 


For the fiscal year ending December 31, 2003, Genome Therapeutics said it expects a net loss of $20 million to $25 million.


Click here for further information.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.